TOP1 — gene · CancerIndex

Curated evidence

Clinical evidence (5)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–5 of 5 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TOP1 Amplification2
Cetuximab + FOLFIRI RegimenCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved33 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Rectum Adenocarcinoma TCGA-READ	Rectal AdenocarcinomaALIAS

Literature

25 per page, newest first.

pubmedPublishedShowing 1–4 of 4 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

TOP1 EXPRESSION2
Carboplatin + Cyclophosphamide + TopotecanCombination	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID910 Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with … (full text at CIViC) PMID 19648970 · Litzow et al., 2010 · Open in CIViC	civic
Irinotecan	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID912 498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a b… (full text at CIViC) PMID 19775480 · Kostopoulos et al., 2009 · Open in CIViC	civic